HRP20120349T1 - Formulacija glatiramer acetata smanjenog volumenai postupci davanja - Google Patents
Formulacija glatiramer acetata smanjenog volumenai postupci davanja Download PDFInfo
- Publication number
- HRP20120349T1 HRP20120349T1 HRP20120349AT HRP20120349T HRP20120349T1 HR P20120349 T1 HRP20120349 T1 HR P20120349T1 HR P20120349A T HRP20120349A T HR P20120349AT HR P20120349 T HRP20120349 T HR P20120349T HR P20120349 T1 HRP20120349 T1 HR P20120349T1
- Authority
- HR
- Croatia
- Prior art keywords
- unit dose
- dose according
- injection
- subcutaneous injection
- glatiramer acetate
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims abstract 9
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims abstract 9
- 229960003776 glatiramer acetate Drugs 0.000 title claims abstract 9
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003186 pharmaceutical solution Substances 0.000 claims abstract 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 7
- 229930195725 Mannitol Natural products 0.000 claims abstract 7
- 235000010355 mannitol Nutrition 0.000 claims abstract 7
- 239000000594 mannitol Substances 0.000 claims abstract 7
- 239000000243 solution Substances 0.000 claims abstract 2
- 238000010254 subcutaneous injection Methods 0.000 claims 12
- 239000007929 subcutaneous injection Substances 0.000 claims 12
- 206010022095 Injection Site reaction Diseases 0.000 claims 7
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 230000000007 visual effect Effects 0.000 claims 4
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27100909P | 2009-07-15 | 2009-07-15 | |
| US27134009P | 2009-07-20 | 2009-07-20 | |
| US33701110P | 2010-01-29 | 2010-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120349T1 true HRP20120349T1 (hr) | 2012-07-31 |
Family
ID=42283140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120349AT HRP20120349T1 (hr) | 2009-07-15 | 2012-04-18 | Formulacija glatiramer acetata smanjenog volumenai postupci davanja |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20110060279A1 (enExample) |
| EP (2) | EP2275086B1 (enExample) |
| JP (1) | JP2012533540A (enExample) |
| AR (1) | AR077484A1 (enExample) |
| AT (1) | ATE549013T1 (enExample) |
| AU (1) | AU2010273234A1 (enExample) |
| BR (1) | BR112012000878A2 (enExample) |
| CA (1) | CA2697570C (enExample) |
| DK (1) | DK2275086T3 (enExample) |
| EA (1) | EA201270167A1 (enExample) |
| ES (1) | ES2383347T3 (enExample) |
| HR (1) | HRP20120349T1 (enExample) |
| IL (1) | IL217240A0 (enExample) |
| MX (1) | MX2012000687A (enExample) |
| PL (1) | PL2275086T3 (enExample) |
| PT (1) | PT2275086E (enExample) |
| RS (1) | RS52367B (enExample) |
| WO (1) | WO2011008274A2 (enExample) |
| ZA (1) | ZA201200586B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US12097357B2 (en) | 2008-09-15 | 2024-09-24 | West Pharma. Services IL, Ltd. | Stabilized pen injector |
| ES2383347T3 (es) * | 2009-07-15 | 2012-06-20 | Teva Pharmaceutical Industries, Ltd. | Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| EA019998B9 (ru) | 2009-08-20 | 2016-01-29 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | Терапия глатирамером ацетатом с низкой кратностью |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| JP2013541010A (ja) | 2010-10-11 | 2013-11-07 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2014029621A1 (en) * | 2012-08-20 | 2014-02-27 | Carebay Europe Ltd | Automatic injection device |
| NZ630421A (en) | 2012-10-10 | 2018-07-27 | Teva Pharma | Biomarkers predictive for clinical response for glatiramer acetate |
| WO2014128079A1 (en) * | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| KR101738889B1 (ko) * | 2013-03-08 | 2017-05-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 주사기용 재사용 가능한 주입기 장치 |
| AU2014229581B2 (en) * | 2013-03-08 | 2016-12-22 | Teva Pharmaceutical Industries Limited | Re-useable injector device for syringe |
| US8591463B1 (en) * | 2013-03-08 | 2013-11-26 | Teva Pharmaceutical Industries Ltd. | Re-useable injector device for syringe |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| RU2728195C2 (ru) | 2014-02-26 | 2020-07-28 | Аллерган, Инк. | Устройство доставки внутриглазного имплантата и способы его использования |
| US9415176B1 (en) | 2015-01-22 | 2016-08-16 | West Pharmaceutical Services, Inc. | Autoinjector having an end-of-dose visual indicator |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| JP7193448B2 (ja) | 2016-08-31 | 2022-12-20 | マピ ファーマ リミテッド | 酢酸グラチラマーを含むデポシステム |
| WO2018083697A1 (en) * | 2016-11-02 | 2018-05-11 | To Pharmaceuticals Llc | Combination therapy of cbd and copaxone |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| WO2019036363A1 (en) | 2017-08-14 | 2019-02-21 | Progenity Inc. | TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE55260T1 (de) * | 1985-10-11 | 1990-08-15 | Duphar Int Res | Automatische spritze. |
| NL8701091A (nl) * | 1987-05-08 | 1988-12-01 | Spruyt Hillen Bv | Injectiepen. |
| US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| GB8926825D0 (en) * | 1989-11-28 | 1990-01-17 | Glaxo Group Ltd | Device |
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US6454746B1 (en) * | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| SE518981C2 (sv) * | 2000-12-14 | 2002-12-17 | Shl Medical Ab | Autoinjektor |
| EP1572271A1 (de) * | 2002-11-25 | 2005-09-14 | Tecpharma Licensing AG | Autoinjektor mit rückstellbarer auslösesicherung |
| JP2007507541A (ja) * | 2003-10-03 | 2007-03-29 | ベイヒル セラピューティクス インコーポレーティッド | 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法 |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| EP1796710A4 (en) * | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| US7560100B2 (en) * | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| ES2331015T3 (es) * | 2004-10-29 | 2009-12-18 | Sandoz Ag | Proceso para la preparacion de un glatiramero. |
| US20070161566A1 (en) * | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20070161960A1 (en) * | 2006-01-12 | 2007-07-12 | Fu-Yuan Li | Lancet device |
| WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| TWI527603B (zh) * | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| USD622374S1 (en) * | 2006-09-06 | 2010-08-24 | Abbott Biotechnology Ltd. | Automatic injection device |
| CA2702437C (en) | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| USD607558S1 (en) * | 2008-09-19 | 2010-01-05 | Becton Dickinson France S.A.S. | Medicine injector |
| ES2383347T3 (es) | 2009-07-15 | 2012-06-20 | Teva Pharmaceutical Industries, Ltd. | Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración |
-
2010
- 2010-04-15 ES ES10160099T patent/ES2383347T3/es active Active
- 2010-04-15 US US12/761,367 patent/US20110060279A1/en not_active Abandoned
- 2010-04-15 CA CA2697570A patent/CA2697570C/en not_active Expired - Fee Related
- 2010-04-15 AT AT10160099T patent/ATE549013T1/de active
- 2010-04-15 RS RS20120188A patent/RS52367B/sr unknown
- 2010-04-15 EP EP10160099A patent/EP2275086B1/en active Active
- 2010-04-15 PT PT10160099T patent/PT2275086E/pt unknown
- 2010-04-15 PL PL10160099T patent/PL2275086T3/pl unknown
- 2010-04-15 DK DK10160099.7T patent/DK2275086T3/da active
- 2010-05-21 US US12/785,125 patent/US7855176B1/en not_active Expired - Fee Related
- 2010-07-14 AU AU2010273234A patent/AU2010273234A1/en not_active Abandoned
- 2010-07-14 BR BR112012000878A patent/BR112012000878A2/pt not_active IP Right Cessation
- 2010-07-14 EA EA201270167A patent/EA201270167A1/ru unknown
- 2010-07-14 WO PCT/US2010/001972 patent/WO2011008274A2/en not_active Ceased
- 2010-07-14 EP EP10800156A patent/EP2453907A2/en not_active Withdrawn
- 2010-07-14 JP JP2012520598A patent/JP2012533540A/ja active Pending
- 2010-07-14 MX MX2012000687A patent/MX2012000687A/es not_active Application Discontinuation
- 2010-07-15 AR ARP100102598A patent/AR077484A1/es unknown
- 2010-11-17 US US12/948,611 patent/US9018170B2/en not_active Expired - Fee Related
-
2011
- 2011-12-27 IL IL217240A patent/IL217240A0/en unknown
-
2012
- 2012-01-24 ZA ZA2012/00586A patent/ZA201200586B/en unknown
- 2012-04-18 HR HRP20120349AT patent/HRP20120349T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010273234A1 (en) | 2012-02-23 |
| AR077484A1 (es) | 2011-08-31 |
| WO2011008274A3 (en) | 2011-09-22 |
| ES2383347T3 (es) | 2012-06-20 |
| JP2012533540A (ja) | 2012-12-27 |
| EP2275086B1 (en) | 2012-03-14 |
| EP2275086A1 (en) | 2011-01-19 |
| US20110066112A1 (en) | 2011-03-17 |
| DK2275086T3 (da) | 2012-07-09 |
| MX2012000687A (es) | 2012-09-07 |
| CA2697570A1 (en) | 2010-06-22 |
| ATE549013T1 (de) | 2012-03-15 |
| ZA201200586B (en) | 2013-10-30 |
| EA201270167A1 (ru) | 2012-08-30 |
| WO2011008274A2 (en) | 2011-01-20 |
| HK1152249A1 (en) | 2012-02-24 |
| US9018170B2 (en) | 2015-04-28 |
| BR112012000878A2 (pt) | 2019-09-24 |
| PT2275086E (pt) | 2012-05-18 |
| CA2697570C (en) | 2011-11-01 |
| WO2011008274A4 (en) | 2011-11-10 |
| IL217240A0 (en) | 2012-02-29 |
| PL2275086T3 (pl) | 2012-09-28 |
| US20110060279A1 (en) | 2011-03-10 |
| EP2453907A2 (en) | 2012-05-23 |
| RS52367B (sr) | 2012-12-31 |
| US7855176B1 (en) | 2010-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120349T1 (hr) | Formulacija glatiramer acetata smanjenog volumenai postupci davanja | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| ES2716906T3 (es) | Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab | |
| JP2015187125A5 (enExample) | ||
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| JP2011241213A5 (enExample) | ||
| HRP20120688T1 (hr) | Re“im doziranja u liječenju traumatske ozljede mozga progesteronom | |
| RU2013123646A (ru) | Комбинированная композиция | |
| RU2011139015A (ru) | Вызываемая медикаментозными средствами липоатрофия для косметических целей | |
| MX2009013183A (es) | Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso. | |
| Ghaaazi Firozsalari et al. | Effect of Shilajit on the levels of pro-inflammatory and anti-inflammation cytokines in hepatic injury in male rats | |
| WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| JP2013520447A5 (enExample) | ||
| WO2014093818A2 (en) | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men | |
| BR112012000773A2 (pt) | Método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes humanos, método para o tratamento de pacientes humanos, método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes, e método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes com risco aumentado de eventos cardiovasculares | |
| Yang et al. | Evaluation of collagen dermal filler with lidocaine for the correction of nasolabial folds: a randomized, double-blind, multicenter clinical trial | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| Aviv et al. | Patterns of local site reactions to subcutaneous glatiramer acetate treatment of multiple sclerosis: a clinicopathological study | |
| Seremet et al. | Nicolau syndrome following intramuscular injection of oxytocin in pregnant women: report of two cases | |
| ES2422563A1 (es) | Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma | |
| TW201129356A (en) | Reduced volume formulation of glatiramer acetate and methods of administration | |
| Nunns | Tackling vulvodynia | |
| Sun et al. | Urolastic: A new medical liquid silicone rubber elastomer compound for penile augmentation in beagle dogs | |
| Ahmad et al. | A study on the effectiveness of intravenous tramadol in the management of severe traumatic pain in emergency department |